GlaxoSmithKline

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.

The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.

Following months of concerns regarding the potential contamination of ranitidine-based products with known carcinogens, the U.S. Food and Drug Administration is asking manufacturers to immediately withdraw all prescription and over-the-counter drugs from the market.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.

The drugs in question bring in about $200 million annually.